Stock Market News & Analysis

stocks
Costs bite as big 4 bank reports
Softer net interest margins and higher expenses in first-half fiscal 2025 profits.
Costs bite as big 4 bank reports
Costs bite as big 4 bank reports
stocks
Amazon earnings: Good quarter overall with AWS decent; Guidance light on operating income

Amazon earnings: Good quarter overall with AWS decent; Guidance light on operating income

Prebuying behavior ahead of tariffs is worth monitoring if the tariff situation persists.
stocks
What Berkshire without Buffett may look like

What Berkshire without Buffett may look like

The 94-year-old will remain Berkshire’s chairman.
stocks
Outlook softens for ASX packaging company

Outlook softens for ASX packaging company

Weak North American volumes temper outlook.
stocks
Tariffs loom large as Apple reports earnings

Tariffs loom large as Apple reports earnings

Company cites a $900 million impact from tariffs.
stocks
Slow and steady at Transurban

Slow and steady at Transurban

Traffic growth reported at the toll-road operator.
stocks
Microsoft earnings: Good quarter from any angle, raising fair value estimate

Microsoft earnings: Good quarter from any angle, raising fair value estimate

Global technology leader continues to perform well.
stocks
3 undervalued ASX companies with sound balance sheets

3 undervalued ASX companies with sound balance sheets

I love investing in companies that boast strong financial positions. These three cheap ASX shares could fit the bill and screen cheaply according to our analysts.
stocks
Overpriced ASX company too successful in wrong channel

Overpriced ASX company too successful in wrong channel

Booming online sales cannibalising more profitable in-store sales.
stocks
More promising signs for ASX listed software player

More promising signs for ASX listed software player

This moated small-cap looks undervalued versus our forecasts. Let alone management’s more ambitious growth targets.
stocks
Overvalued ASX pharma play hits FDA speedbump

Overvalued ASX pharma play hits FDA speedbump

We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.
stocks
Going into earnings, is Meta stock a buy, a sell, or fairly valued?

Going into earnings, is Meta stock a buy, a sell, or fairly valued?

Watching AI monetization, Reels profitability, and Reality Labs spending, here’s what we think of Meta stock.
stocks
Alphabet earnings: Solid results as AI monetization continues to improve

Alphabet earnings: Solid results as AI monetization continues to improve

We continue to view the stock as materially undervalued.
stocks
The most hated company on the ASX 200 right now

The most hated company on the ASX 200 right now

Down more than 70% in the last year is this share a bargain?
stocks
10 best US dividend aristocrats to buy now

10 best US dividend aristocrats to buy now

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
ASX healthcare leader continues to prove the doubters wrong

ASX healthcare leader continues to prove the doubters wrong

Niche play with more growth potential than many investors give it credit for.
of 233
Viewing 1 to 16 of 3716